EMA approved orphan medicines since the implementation of the orphan legislation

Abstract Background In the European Union (EU), the orphan legislation, aiming to increase the number of pharmacotherapies available for rare diseases, came into force in April 2000. This study examined the development of the selection of orphan medicines granted marketing authorisation, their appro...

Full description

Saved in:
Bibliographic Details
Main Authors: Eveliina Hahl, Terhi Kurko, Hanna Koskinen, Marja Airaksinen, Kati Sarnola
Format: Article
Language:English
Published: BMC 2025-06-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Online Access:https://doi.org/10.1186/s13023-025-03756-7
Tags: Add Tag
No Tags, Be the first to tag this record!